PremiumThe FlyMural Oncology halting progress of nemvaleukin trial in ovarian cancer Mural Oncology downgraded to Hold from Buy at JonesResearch Mural Oncology downgraded to Outperform from Strong Buy at Raymond James PremiumCompany AnnouncementsMural Oncology Highlights 2024 Financial Results and Strategic Focus Mural Oncology reports Q4 EPS ($2.01), consensus ($1.96) Promising Prospects for Mural Oncology: Buy Rating Justified by Strong Pipeline and Financial Position PremiumThe FlyMural Oncology reports Q3 EPS ($1.87), consensus ($1.95) MURA Earnings this Week: How Will it Perform? Mural Oncology initiated with a Buy at H.C. Wainwright 
